Inventiva (NASDAQ:IVA) Shares Down 3.2% – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares traded down 3.2% during mid-day trading on Friday . The stock traded as low as $4.21 and last traded at $4.4550. 61,263 shares changed hands during trading, a decline of 22% from the average session volume of 78,359 shares. The stock had previously closed at $4.60.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright raised their price target on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Guggenheim cut their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Piper Sandler began coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Inventiva Trading Down 7.4%

The company has a 50-day moving average price of $4.93 and a 200-day moving average price of $4.24.

Institutional Investors Weigh In On Inventiva

Several hedge funds have recently bought and sold shares of IVA. Millennium Management LLC acquired a new position in shares of Inventiva in the 3rd quarter valued at $649,000. NewEdge Advisors LLC bought a new position in Inventiva during the third quarter worth about $116,000. Creative Planning bought a new position in Inventiva during the second quarter worth about $32,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the period. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.